Personalized antibiotic strategy aims to shield kidney transplant patients from deadly infections
NCT ID NCT07407673
First seen Feb 12, 2026 · Last updated May 07, 2026 · Updated 15 times
Summary
This study tests whether giving a daily antibiotic (pivmecillinam) to kidney transplant recipients at high risk of bloodstream infections can reduce their chance of getting one. 150 participants will receive either the antibiotic or a placebo for 6 months after transplant. The goal is to see if this personalized approach can lower infections, hospital stays, and improve quality of life without causing antibiotic resistance.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aarhus University Hospital
Aarhus, Denmark
Contact
-
Odense University Hospital
Odense, Denmark
Contact
-
Rigshospitalet
Copenhagen, 2100, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.